B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion

Cancer Immunology Immunotherapy

Volumn 48, Issue 10, 2000, Pages 541-549

  Barbera Guillem, Emilio ^a   Nelson, M Bud ^a   Barr, Barbara ^a   Nyhus, Julie K ^a   May Jr , Kenneth F ^a   Feng, Lan ^a   Sampsel, James W ^a  

^a BioCrystal Ltd   (United States)

Author keywords

B cell depletion; Cancer therapy; CD21 hyperexpression

Indexed keywords

CD19 ANTIGEN; CISPLATIN; COMPLEMENT COMPONENT C3D RECEPTOR; DOXORUBICIN; ETHIODIZED OIL; IMMUNOGLOBULIN M ANTIBODY; MITOMYCIN C; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER INVASION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; LYMPH NODE; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; TUMOR ESCAPE; TUMOR VASCULARIZATION;

EID: 0033988580     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006672     Document Type: Article

References (33)

1. 1. Allison AC (1998) The mode of action of immunological adjuvants. Dev Biol Stand 92:3
2. 2. Bansal SC, Bansal BR, Thomas HL, Siegel PD, Rhoads JE Jr, Cooper DR, Terman DS, Mark R (1978) Ex vivo removal of serum IgG in a patient with colon carcinoma: some biochemical, immunological and histological observations. Cancer 42:1
3. 3. Reference deleted
4. 4. Barbera-Guillem E, May KF Jr, Nyhus JK, Nelson MB (1999) Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasma (in press)
5. 5. Behr SI, Korinth D, Schriever F (1998) Differential adhesion pattern of B cell chronic lymphocytic leukemia cells. Leukemia 12:71
6. 6. Brodt P, Gordon J (1978) Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol 121:359
7. 7. Brodt P, Gordon J (1981) Anti-tumor immunity in B lymphocyte-deprived mice. II. In vitro studies. Cell Immunol 65:20
8. 8. Fennelly DW, Norton L, Sznol M, Hakes TB (1995) A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer. Cancer 75:2099
9. 9. Fischer MB, Goerg S, Shen L, Prodeus AP, Goodnow CC, Kelsoe G, Carroll MC (1998) Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 280:582
10. 10. Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, Arcuri R, Abbolito MR, Casale V, Pericoli MN, Vecchione A, Casciani CU, Greiner JW, Schlom J (1996) Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay. Cancer Res 56:5293
11. 11. Gupta VK, McConnell I, Dalziel RG, Hopkins J (1998) Two B cell subpopulations have distinct recirculation characteristics. Eur J Immunol 28:1597
12. 12. Hunter RL, Ferguson DJ, Coppleson LW (1975) Survival with mammary cancer related to the interaction of germinal center hyperplasia and sinus histiocytosis in axillary and internal mammary lymph nodes. Cancer 36:528
13. 13. Koeppen HK, Singh S, Stauss HJ, Park BH, Rowley DA, Schreiber H (1993) CD-4-positive and B lymphocytes in transplantation Immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes. Transplantation 55:1349.
14. 14. Leget GA, Czuczman MS (1998) Use of Rituximab, the new FDA-approved antibody. Curr Opin Oncol 10:548
15. 15. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L (1995) Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1:1179
16. 16. Manson LA (1994) Anti-tumor immune responses of the tumor-bearing host: the case for antibody-mediated immunologic enhancement. Clin Immunol Immunopathol 72:1
17. + and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 55:1356
18. 18. Nagar B, Jones RG, Diefenbach RJ, Isenman DE, Rini JM (1998) X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 280:1277
19. 19. Olesen EH, Johnson AA, Damgaard G, Leslie RG (1998) The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells. Immunology 93:177
20. 20. Petrarca C, Casalino B, von-Mensdorff-Pouilly S, Rughetti A, Rahimi H, Scambia G, Hilgers J, Frati L, Nuti M (1999) Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads. Cancer Immunol Immunother 47:272
21. 21. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon Cardo C, Catoretti G, Fisher PE, Parsons R (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96:1563
22. 22. Prehn RT (1972) The immune reaction as an stimulator of tumor growth. Science 176:170
23. 23. Punt CJA, Barbuto JAM, Zhang H, Grimes WJ, Hatch KD, Hersh EM (1994) Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes. Cancer Immunol Immunother 38:225
24. 24. Quin Z, Richter G, Shuler T, Ibe S, Cao X, Blankenstein T (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4:627
25. 25. Ravindranath MH, Kelley MC, Jones RC, Amiri AA, Bauer PM, Morton DL (1998) Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Int J Cancer 75:117
26. 26. Rijkers GT, Sanders EA, Breukels MA, Zegers BJ (1998) Infant B cell responses to polysaccharide determinants. Vaccine 16:1396
27. 27. Rowley DA, Stach RM (1998) B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses. Int Immunol 10:355
28. 28. Schneebaum S, Arnold MW, Houchens DP, Greenson JK, Cote RJ, Hitchcock CL, Young DC, Mojzisik CM, Martin-EW Jr (1995) The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer 75:2809
29. 29. Springer GF (1997) Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 75:594
30. 30. Tolnay M, Tsokos GC (1998) Complement receptor 2 in the regulation of the immune response. Clin Immunol Immunopathol 88:123
31. 31. Wang BL, Springer GF, Kaufman MW (1996) Concurrent immunohistochemical staining of tumor-infiltrating lymphocytes and carcinoma-associated T (Thomsen-Friedenreich)/Tn antigens in human breast carcinoma. J Histochem Cytochem 44:187
32. 32. Xu Y, Silver DF, Yang NP, Oflazoglu E, Hempling RE, Piver MS, Repasky EA (1999) Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol 72:161
33. 33. Ziv Y, Shohat B, Gelerenter I, Wolloch Y (1991) B lymphocyte changes induced by peri-operative blood transfusions and surgery in patients with colorectal cancer. Isr J Med Sci 27:75